These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1831437)

  • 1. Treatment with different GnRH analogues in women: preliminary evidence for disparant effects on serum androgen concentrations.
    Rossmanith WG; Wirth U; Sasse V; Lauritzen C
    Horm Metab Res; 1991 Apr; 23(4):198-9. PubMed ID: 1831437
    [No Abstract]   [Full Text] [Related]  

  • 2. [Differential effects of GnRH analogs on androgen concentrations in females].
    Wirth U; Rossmanith WG; Sasse V; Lauritzen C
    Gynakol Rundsch; 1991; 31 Suppl 2():400-2. PubMed ID: 1838737
    [No Abstract]   [Full Text] [Related]  

  • 3. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 4. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.
    Eisenberger MA; O'Dwyer PJ; Friedman MA
    J Clin Oncol; 1986 Mar; 4(3):414-24. PubMed ID: 2936872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 6. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Luteinizing hormone-releasing hormone agonists for treatment of breast cancer].
    Gez E; Kovner F
    Harefuah; 1990 Jun; 118(11):655-8. PubMed ID: 2143745
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment with an LHRH analogue in patients with advanced pancreatic cancer. A preliminary report.
    Andrén-Sandberg A
    Acta Chir Scand; 1990 Aug; 156(8):549-51. PubMed ID: 2146849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
    Waxman J; Man A; Hendry WF; Whitfield HN; Besser GM; Tiptaft RC; Paris AM; Oliver RT
    Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1387-8. PubMed ID: 2933122
    [No Abstract]   [Full Text] [Related]  

  • 11. [GnRH agonists in the ovulation stimulation scheme for in vitro fertilization].
    Roztocil A; Pilka L; Holubová M
    Cesk Gynekol; 1989 Dec; 54(10):776-82. PubMed ID: 2534286
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale in use of LHRH analogues in endometriosis.
    Shaw RW
    Horm Res; 1989; 32 Suppl 1():110-4. PubMed ID: 2533143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical appreciation of LHRH analogue formulations.
    Lemay A
    Horm Res; 1989; 32 Suppl 1():93-101; discussion 102. PubMed ID: 2533161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gonadotropin-releasing hormone variants on plasma and testicular androgen levels in intact and hypophysectomized male frogs, Rana esculenta.
    D'Antonio M; Fasano S; de Leeuw R; Pierantoni R
    J Exp Zool; 1992 Jan; 261(1):34-9. PubMed ID: 1729384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of cancer of the prostate. Role of gonadorelin analogs].
    Steg A
    Presse Med; 1989 May; 18(20):1007-9. PubMed ID: 2524792
    [No Abstract]   [Full Text] [Related]  

  • 16. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
    Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary endometriosis: conservative treatment with GnRH agonists.
    Espaulella J; Armengol J; Bella F; Lain JM; Calaf J
    Obstet Gynecol; 1991 Sep; 78(3 Pt 2):535-7. PubMed ID: 1831251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 19. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.
    Lemay A
    Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of GnRH depot analogue in the treatment of uterine fibroids.
    Auber G; Ricci G; Barciulli F; Pregazzi R; D'Ancona RL; Toffoletti FG
    Acta Eur Fertil; 1990; 21(4):185-9. PubMed ID: 2150737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.